fda approves first oral glp-1 obesity drug august 1 2025 GLP1 Foundayo Novo Nordisk's weight-loss pill wins
Description
For patients seeking non-pharmaceutical approaches to enhance incretin function, comprehensive lifestyle modifications remain the foundation of evidence-based care
Reduce or eliminate processed foods, excess added sugars, and vegetable oils
What kind of weight loss can I expect
Alter, M
Patients: Adults 18 years eligible for anti-obesity medication
Cong, Z
